NAMS financials
NewAmsterdam Pharma (NAMS) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
NAMS income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $22.50M | $22.44M | -$225.68M | -$203.82M | -1.75 |
| 2024 | $45.56M | $45.56M | -$176.29M | -$241.60M | -2.56 |
| 2023 | $14.09M | $14.09M | -$182.97M | -$176.94M | -2.15 |
| 2022 | $102.69M | $102.69M | -$3.56M | -$22.63M | -1.19 |
| 2021 | $0.00 | $0.00 | -$34.98M | -$41.78M | -3.34 |
| 2020 | $0.00 | $0.00 | -$6.63M | -$7.02M | 0.00 |
- NAMS revenue was $22.50M in fiscal 2025, net income -$203.82M.
Updated 2026-11-07 11:55 UTC